More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
By identifying these structural changes prior to the onset of symptomatic neurodegeneration, providers may be able to initiate preventive therapies sooner.
The new F-18 flurpiridaz radiotracer is expected to help drive cardiac PET growth, but it requires waiting between rest and stress scans. Software from MultiFunctional Imaging can help care teams combat that problem.
Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.
Sola is a rupture-resistant balloon catheter that uses laser energy to deliver 360-degree pressure with each pulse. It was designed to address limitations the company saw in current calcium-modification devices.
